Novel Technologies for Heart Failure and Atrial Fibrillation
This study aims to improve how doctors measure the heart's pumping ability in people who have both heart failure and atrial fibrillation (an irregular heartbeat). Currently, it's hard to accurately assess how severe the heart is affected in these patients, which makes it difficult to diagnose and treat them effectively. Researchers will look at new ways to use echocardiograms (heart ultrasounds) and other information to better estimate the pressure inside the heart's main pumping chamber (left ventricle). The goal is to develop a reliable method to tell if this pressure is too high, which could help doctors provide better care and predict who might be at higher risk for hospital stays or other problems. About 400 participants will be included in this study.
- Study design
- This is an observational study involving about 400 participants. It will look at information from people who already have heart failure and atrial fibrillation.
- What's involved
- You would undergo an echocardiogram and an invasive heart pressure measurement (RHC or LHC) within 8 hours of each other, without changes to your heart medications in between.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 3 years after recruitment ends to observe outcomes related to mortality and heart-failure hospitalization.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation
At a glance
Conditions
NCT07436299
Where you'd take part
This study runs at 15 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium
Aalst, Belgiumstudy coordinator listed
Not yet recruiting
Carol Davila University of Medicine and Pharmacy
Bucharest, Romaniastudy coordinator listed
Not yet recruiting
Catholic University of Leuven
Leuven, Belgiumstudy coordinator listed
Not yet recruiting
Cleveland Clinic
Cleveland, Ohiostudy coordinator listed
Not yet recruiting
Department of Cardiovascular Sciences, University of Birmingham
Birmingham, United Kingdomstudy coordinator listed
Not yet recruiting
Division of Cardiovascular & Pulmonary Diseases, Oslo University Hospital
Oslo, Oslo, Norwaystudy coordinator listed
Recruiting
Ehime University
Tōon, Ehime, Japanstudy coordinator listed
Not yet recruiting
King's College
London, United Kingdomstudy coordinator listed
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Otto Armin Smiseth, Professor, Medical Doctor · STUDY_CHAIR · Oslo University Hospital
- Thor Edvardsen, Professor, Medical Doctor · STUDY_DIRECTOR · Oslo University Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Diagnostic accuracy of a non-invasive algorithm for classification of left ventricular filling pressure in atrial fibrillation• Start recruitment: February 2026 • End recruitment: January 2028 • Follow-up: 3 years • Data analysis: Ferbuary 2026 - December 2028. Outcome analysis will be extended to 3 years of follow-up. • Manuscript preparation: December 2028 - December 2029
Main aim of the study is to develop and validate a clinically applicable algorithm combining echocardiographic and clinical parameters to differentiate normal from elevated LV filling pressure in AF with ≥80% diagnostic accuracy. Left venticular filling pressures will be measured during right- or left-sided heart catehterization and left ventricular filling pressure \>15 mmHg will be considered elevated.
- Imaging markers associated with mortality and heart-failure hospitalization in atrial fibrillation• Start recruitment: February 2026 • End recruitment: January 2028 • Follow-up: 3 years • Data analysis: Ferbuary 2026 - December 2028. Outcome analysis will be extended to 3 years of follow-up. • Manuscript preparation: December 2028 - December 2029
To identify prognostic imaging markers associated with mortality and heart-failure hospitalization over a 3-year follow-up period.